Európska únia - slovinčina - EMA (European Medicines Agency)

intervet international bv - rezokortol butirat - kortikosteroidi, dermatološki preparati - psi - zdravljenje akutnega lokaliziranega vlažnega dermatitisa.

Európska únia - slovinčina - EMA (European Medicines Agency)

nova laboratories ireland limited - 6-merkaptopurin monohidrat - leukemija, limfid - antineoplastična sredstva - zdravilo xaluprine je indicirano za zdravljenje akutne limfoblastne levkemije (all) pri odraslih, mladostnikih in otrocih.

Európska únia - slovinčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - necitumumab - karcinom, pljučni pljuč - antineoplastična sredstva - portrazza v kombinaciji s kemoterapijo gemcitabin in cisplatinom indicirano za zdravljenje odraslih bolnikov z lokalno napredovalim ali metastatskim epidermalni rastni faktor receptor (egfr) izražanje ploščatocelični nedrobnoceličnim pljučnim rakom ki niso prejel pred kemoterapijo za ta pogoj.

Európska únia - slovinčina - EMA (European Medicines Agency)

servier (ireland) industries ltd - agomelatine - depresivna motnja, major - psychoanaleptics, - zdravljenje velikih depresivnih epizod pri odraslih.

Európska únia - slovinčina - EMA (European Medicines Agency)

les laboratoires servier - agomelatine - depresivna motnja, major - psychoanaleptics, - zdravljenje velikih depresivnih epizod pri odraslih.

Európska únia - slovinčina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus varicella-zoster (v živo, oslabljen) - herpes zoster; immunization - virusna cepiva - zdravilo zostavax je indicirano za preprečevanje herpes zoster ("zoster" ali pasovec) in posterpetične nevralgije povezane s herpes-zosterom. zostavax je označen za imunizacijo posameznikov 50 let ali starejši.

Európska únia - slovinčina - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 in 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Európska únia - slovinčina - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - cepiva - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. uporaba shingrix mora biti v skladu z uradnimi priporočili.

Európska únia - slovinčina - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemoragične mrzlice, ebola - cepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Európska únia - slovinčina - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemoragične mrzlice, ebola - cepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.